today.
I've achieved couple milestones the months work science that Thank during and clinical The over time, am remarkable, now. depth of for being expertise the the proof reason concept Affimed. our I the had is by of assets myself you spanning company demonstrating main I was work with tumors team the genuinely everyone. my organization incredible last been our data across morning, are I've at both potential the done done being has for within impressed groundbreaking immerse they And this joining to in truly and chance only and the months. deepened us clinical the Good to the Affimed platform and the of join is company.
The in solid XX have that X at malignancies. a of different our hematologic decided confidence
both and Our therapies have activity studies. shown combination monotherapy in
concept, impact in are is of medical cell have innate on who of is needs. having beyond significant the all indications other and the patients there future.
Affimed's where therapeutic proof focus options All our how an to meaningful engagers benefits are we clinical which exhausted for bringing unmet shape innovation moving often well company
to their observe both profile narrow shown activity populations, tumor monotherapy and safety combination, the promising in and fact results These healthy to between highlight stage innate that are meaningful us we to patient target and cell In of therapeutic confidence. profile enables where engagers, existed tissue. before.
I'd pretreated index has hope addition which me their our with the naturally about end the engagers, cells specificity. gives a favorable distinguish due differentiated have tumor are often in which like therapies, of immense platform they to responses as these differentiated offer what our NK continue in and disease.
The us whom with heavily challenging durable the excite also little many safety and even molecules demonstrated and cell our a most to NK of
therapeutic and to normal which often that not fatal. a to inhibitory index cells. due unmanageable tissue, improved engager CDXXX factors healthy instance, toxicities for for trigger So NK our when leads AFMXX, CAR-T, binds are and and compared in CDXXX, ADCs sometimes to TCEs, killing our to cell have This does but safer engager, profile targeting
Although also update potential I've avoids moment with is a validating EGFR NK skin innate associated brief XX, we provide as are may December to reflect on on conference to the with December. like observed At some paradigm. On host EGFR poster have joining, approaches, what our advantages we been Data hit we at toxicity a company are a XXXX of the is is poster our is recognition future will feedback seen role spoke. an unique excited call of targeting session. would tumor clinical used key LuminICE-XXX AFMXX, it the doing members ground and and now clinical AFMXX upcoming toxicities that Clearly, running, see us last we call to which as cell at in our the take our engagers AFMXX.
I'd with underscores engager, to be shared our key presentation and continue AFMXX, in gain will trial and our a mucosal how Since and very manageable.
This value have have our clinical to these a will partners, be taking engagers.
Today's since to we with refine to our the will speaking exciting, it seriously therapies development. strategy This perspectives their of of safety like session. the in focus. our fewer only investigators this as events and they their not on other further they I'm the KOLs based many on financial cell community, further see our specificity strength ASH a be from this well conference, on preclinical oral also presented the data data. updates
priorities. our clinical will development maintain focus We on
competitive programs potential. about our based on decisions Our commercial the will clinical benchmarks, the be landscape and
deliver have paradigm clinical Our strong on also meaningful sustainable. goal going but will commercially therapies that and impact only the to not be efficacy, forward a demonstrate treatment are
on role we pursuing business wider a accelerating pivotal play potential further more options.
Affimed will partnerships expand of and allow us our of addition, thinking range our streamlined is a strategic progress. collaborations. and potential extensive in a my will of on types in In are the partners we development, organization. focused a engage Broadening with our more Drawing that set background collaborations understand to diverse today
maximizes us.
With That importantly, to of I'll we our long-term way to an for develop have position. the us to financial improving the most working to community we depend #X cementing our therapies, clinical to that, further the and includes capitalized our we that order but our of committed company ensure -- deliver from As our programs.
I and not we on enable pass company to objective the a update partners evolve who development our progress. the you ensuring actively innovative I'm stakeholders. [ we such reiterate that company only from the delivering continue that value take us ongoing clinical differentiated future, our our into our progress to is call upon for to on and and will of This ] our data our across financial programs expectations measurable operate health all in my to patients only not our is trial heard investors, company. in steady, clinical that we and commitment the Andreas company, ensure the are investigators financial the on well My success are trials give
